论文部分内容阅读
氨苯砜、氯喹、乙胺嘧啶三药联用(称“治疟宁”)对治疗间日疟有明显增效及减低氯喹抗药性作用,但不能控制复发。而氨苯砜与伯氨喹啉联用则可致紫绀发生率增高。作者试用“治疟宁”一日2剂后48小时每日加服伯氯喹啉连服6日的方案,治疗现症患者119例(“治、伯”组),并与单独氯喹联用伯氨喹啉治疗60例(“氯、伯”组)作对照。结果表明,“治、伯”组既可保持“治疟宁”的特点,又可控制近期复发及紫绀的发生,对控制传播及保护劳动力有一定意义。
Dapsone, chloroquine, pyrimethamine triadimetic (referred to as “cure malaria”) on the treatment of vivax significant synergy and reduce chloroquine resistance, but can not control the recurrence. The combination of dapsone and primaquine can lead to an increased incidence of cyanosis. The trial of “cure malathion” on the 1st after 48 hours two times a day plus clothing regimen with regimen on the 6th, the treatment of 119 cases of patients (“governance, primary” group), and with chloroquine alone Union Aminoquinoline treatment of 60 cases (“chlorine, Bo” group) as a control. The results showed that the “Zhubi” group can not only maintain the characteristics of “treating malaria,” but also control the recurrence and the occurrence of cyanosis in the near future, which is of some significance for the control of transmission and the protection of the labor force.